

Gabriela S Hobbs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2490484/publications.pdf>

Version: 2024-02-01

110
papers

2,552
citations

304743

22
h-index

223800

46
g-index

111
all docs

111
docs citations

111
times ranked

2749
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 12-23.	1.6	75
2	Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults. <i>Leukemia and Lymphoma</i> , 2022, 63, 1428-1435.	1.3	3
3	Chemotherapy Resistance in B-ALL with Cryptic <i>NUP214-ABL1</i> Is Amenable to Kinase Inhibition and Immunotherapy. <i>Oncologist</i> , 2022, 27, 82-86.	3.7	5
4	Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients. <i>Leukemia</i> , 2022, 36, 1176-1179.	7.2	3
5	Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms. <i>Experimental Hematology</i> , 2022, 107, 14-19.	0.4	10
6	Factors Associated with Health Care Utilization at the End of Life for Patients with Acute Myeloid Leukemia. <i>Journal of Palliative Medicine</i> , 2022, 25, 749-756.	1.1	3
7	Incidence of bleeding events in patients on concomitant tyrosine kinase inhibitors and selective serotonin reuptake inhibitors. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522210980.	0.9	0
8	Abstract CT541: Efficacy and safety of pascalisib-ruxolitinib combination therapy in myelofibrosis patients (Pts) with low vs higher baseline platelet count (PC): A subgroup analysis of data from a phase 2 study. <i>Cancer Research</i> , 2022, 82, CT541-CT541.	0.9	1
9	Psychological mobile app for patients with acute myeloid leukemia (AML): A randomized clinical trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12018-12018.	1.6	0
10	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	10
11	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> , 2022, 140, 1200-1228.	1.4	814
12	Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia. <i>JAMA Oncology</i> , 2021, 7, 238.	7.1	90
13	Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. <i>Cell Stem Cell</i> , 2021, 28, 514-523.e9.	11.1	130
14	Posttraumatic stress disorder symptoms in patients with acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2500-2506.	4.1	14
15	Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Oncologist</i> , 2021, 26, e2082-e2085.	3.7	2
16	PD-1 inhibition in advanced myeloproliferative neoplasms. <i>Blood Advances</i> , 2021, 5, 5086-5097.	5.2	16
17	Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 473-482.	2.3	3
18	Future Directions in Chronic Phase CML Treatment. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 500-508.	2.3	12

#	ARTICLE	IF	CITATIONS
19	Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients. <i>Blood Cancer Journal</i> , 2021, 11, 176.	6.2	13
20	Pulmonary Hypertension Is Associated with Poor Outcomes in Patients with Myeloproliferative Neoplasms and Cardiovascular Disease. <i>Blood</i> , 2021, 138, 3653-3653.	1.4	2
21	Antibody and T-Cell Responses to COVID-19 Vaccination in Myeloproliferative Neoplasm Patients. <i>Blood</i> , 2021, 138, 316-316.	1.4	1
22	A Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Celltransplantation for Patients with Primary or Secondary Myelofibrosis. <i>Blood</i> , 2021, 138, 169-169.	1.4	4
23	Immune Profiling of Responses to Influenza Vaccination in Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2021, 138, 3631-3631.	1.4	0
24	MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination. , 2021, 9, A807-A807.		0
25	Increased Risk of Thrombosis in Patients with Myeloproliferative Neoplasms Compared with the General Population Hospitalized with COVID-19. <i>Blood</i> , 2021, 138, 1508-1508.	1.4	0
26	Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3K γ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF). <i>Blood</i> , 2021, 138, 3647-3647.	1.4	2
27	A phase 1 study of the antibody-drug conjugate brentuximab vedotin with induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 1264-1273.	4.1	15
28	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e122-e133.	4.6	19
29	Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. <i>Leukemia Research</i> , 2020, 98, 106459.	0.8	16
30	Long-term molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy. <i>Leukemia</i> , 2020, 34, 3050-3054.	7.2	3
31	Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia. <i>Blood Advances</i> , 2020, 4, 3136-3140.	5.2	28
32	Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. , 2020, 8, e001435.		87
33	The Art of Oncology: COVID-19 Era. <i>Oncologist</i> , 2020, 25, 997-1000.	3.7	6
34	Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature. <i>Cancers</i> , 2020, 12, 1954.	3.7	39
35	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , 2020, 7, e601-e612.	4.6	56
36	Case Presentation: A Young Man with Polycythemia Vera and Fatigue. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S18.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Case Presentation "Thrombosis in PV: How to Predict and How to Reduce Risk. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S74-S75.	0.4	0
38	Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 2020, 4, 1965-1973.	5.2	63
39	Incidence of Invasive Fungal Infections in Acute Myeloid Leukemia Without Antifungal Prophylaxis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e883-e889.	0.4	4
40	A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia. Blood Advances, 2020, 4, 445-448.	5.2	11
41	Acute kidney injury after ruxolitinib: Common complication, uncommon cause. American Journal of Hematology, 2020, 95, E181-E183.	4.1	2
42	Antiemetic prophylaxis for induction chemotherapy in patients with acute myeloid leukemia. Journal of Oncology Pharmacy Practice, 2020, 26, 1213-1215.	0.9	2
43	Clinical response to larotrectinib in adult Philadelphia chromosome"like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Advances, 2020, 4, 106-111.	5.2	23
44	Results of a Phase II Study of PD-1 Inhibition in Advanced Myeloproliferative Neoplasms. Blood, 2020, 136, 14-15.	1.4	6
45	Evaluation of a Pan-Lysyl Oxidase Inhibitor, Pxs-5505, in Myelofibrosis: A Phase I, Randomized, Placebo Controlled Double Blind Study in Healthy Adults. Blood, 2020, 136, 16-16.	1.4	8
46	A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for <i>IDH2</i>-Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation. Blood, 2020, 136, 4-5.	1.4	6
47	Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2-Mutant Myeloproliferative Neoplasms. Blood, 2020, 136, 7-8.	1.4	4
48	Multisite randomized trial of integrated palliative and oncology care for patients with acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2020, 38, 12000-12000.	1.6	9
49	Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1248-1269.	4.9	21
50	Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1385-1415.	4.9	147
51	Concurrent FLT3 Inhibitor and IDH Inhibitor Therapy in Patients with Acute Myeloid Leukemia (AML). Blood, 2020, 136, 11-12.	1.4	4
52	A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1271-1278.	4.9	5
53	Factors Associated with High Healthcare Utilization at the End-of-Life (EOL) for Patients with Acute Myeloid Leukemia. Blood, 2020, 136, 24-25.	1.4	0
54	444"..."MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
55	Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults. <i>Blood</i> , 2020, 136, 7-8.	1.4	0
56	Rates of Thrombotic Events in Hypereosinophilic Syndrome and the Effect of Molecular Aberrations in Thrombotic Risk. <i>Blood</i> , 2020, 136, 14-14.	1.4	0
57	A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies. <i>Blood</i> , 2020, 136, 5-6.	1.4	0
58	Post-Traumatic Stress Disorder (PTSD) Symptoms in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 44-45.	1.4	1
59	Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults. <i>Blood</i> , 2020, 136, 41-42.	1.4	1
60	Multi-Site Randomized Trial of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 26-27.	1.4	0
61	Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. <i>Oncologist</i> , 2019, 24, 247-254.	3.7	55
62	Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. <i>Cancer</i> , 2019, 125, 3845-3852.	4.1	10
63	Mutant calreticulin in myeloproliferative neoplasms. <i>Blood</i> , 2019, 134, 2242-2248.	1.4	52
64	Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2019, 60, 3058-3062.	1.3	4
65	Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. <i>Leukemia</i> , 2019, 33, 2393-2402.	7.2	44
66	Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. <i>Human Pathology</i> , 2019, 86, 1-11.	2.0	24
67	Isocitrate dehydrogenase 1 and 2 mutations, 2-oxoglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 541-549.	4.1	23
68	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. <i>Blood</i> , 2019, 134, 4172-4172.	1.4	6
69	Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCM1-FGFR1 Fusion: Data from an Expanded Access Program. <i>Blood</i> , 2019, 134, 5371-5371.	1.4	0
70	Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 202-211.	2.3	33
71	Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms. <i>Haematologica</i> , 2018, 103, e5-e9.	3.5	18
72	Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. <i>Cancer</i> , 2018, 124, 306-314.	4.1	23

#	ARTICLE	IF	CITATIONS
73	A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, 254-261.	4.1	12
74	Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 988-991.	1.3	3
75	Outcomes and predictors of survival in blast phase myeloproliferative neoplasms. <i>Leukemia Research</i> , 2018, 70, 49-55.	0.8	24
76	Lenalidomide combined with mismatched microtransplantation for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E331-E333.	4.1	5
77	Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 766-766.	1.4	9
78	Quality of life and psychological distress in patients with acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2018, 36, 154-154.	1.6	1
79	Quality of life and psychological distress in patients with acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7035-7035.	1.6	1
80	The effect of pre-transplant JAK 1/2 inhibitors on outcomes of myelofibrosis patients who receive allogeneic stem cell transplant.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7072-7072.	1.6	0
81	Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults. <i>Blood</i> , 2018, 132, 2704-2704.	1.4	0
82	The Effect of JAK 1/2 Inhibitors on Outcomes of Allogeneic Stem Cell Transplantation for Patients with Myelofibrosis. <i>Blood</i> , 2018, 132, 5784-5784.	1.4	0
83	Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults. <i>Blood</i> , 2018, 132, 4059-4059.	1.4	0
84	Clinical Outcomes Following Frontline Chemotherapy for Patients with Myeloid Malignancies Harboring Splicing Factor Mutations. <i>Blood</i> , 2018, 132, 4364-4364.	1.4	0
85	Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 2291-2291.	1.4	0
86	Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score. <i>Blood</i> , 2018, 132, 4288-4288.	1.4	0
87	Outcomes for Older Patients with Acute Myeloid Leukemia after Admission to the Intensive Care Unit (ICU). <i>Blood</i> , 2018, 132, 4750-4750.	1.4	0
88	Efficacy of Lenalidomide and Bortezomib for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 4587-4587.	1.4	0
89	Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1431-1431.	1.4	0
90	Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study. <i>Cancer</i> , 2017, 123, 2561-2569.	4.1	33

#	ARTICLE	IF	CITATIONS
91	The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 613-626.	2.2	20
92	Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 719-727.	3.5	33
93	Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. <i>Blood Advances</i> , 2017, 1, 2032-2040.	5.2	53
94	Cytogenetic evolution between diagnosis and relapse and impact on acute myeloid leukemia (AML) reinduction outcomes.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18509-e18509.	1.6	1
95	Perceptions of prognosis and treatment risk in older patients with acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2017, 35, 43-43.	1.6	1
96	Response to induction or hypomethylating agent therapy among patients with myeloproliferative neoplasms progressing to accelerated or leukemic phase.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18561-e18561.	1.6	0
97	A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database. <i>Leukemia and Lymphoma</i> , 2016, 57, 1-4.	1.3	18
98	Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. <i>Lancet Haematology</i> , 2016, 3, e276-e283.	4.6	19
99	New drugs for myelofibrosis. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 521-529.	0.8	2
100	Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients. <i>Journal of Clinical Medicine</i> , 2015, 4, 488-503.	2.4	16
101	The role of families in decisions regarding cancer treatments. <i>Cancer</i> , 2015, 121, 1079-1087.	4.1	117
102	Clinical and molecular genetic characterization of myelofibrosis. <i>Current Opinion in Hematology</i> , 2015, 22, 177-183.	2.5	14
103	Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. <i>Journal of Clinical Oncology</i> , 2015, 33, 3953-3960.	1.6	69
104	Outcomes for Older Patients with Acute Myeloid Leukemia Admitted to the Intensive Care Unit. <i>Blood</i> , 2015, 126, 2104-2104.	1.4	2
105	Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2597-2597.	1.4	6
106	Infectious complications in AML patients treated with induction vs. hypomethylating therapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7065-7065.	1.6	0
107	Potentially avoidable hospitalizations in older patients with acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2015, 33, 206-206.	1.6	0
108	Health Care Utilization and End of Life Care for Older Patients with Acute Myeloid Leukemia Receiving Supportive Care Alone. <i>Blood</i> , 2015, 126, 2126-2126.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Potentially Avoidable Hospitalizations in Older Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 3310-3310.	1.4	0
110	A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies. <i>EJHaem</i> , 0, , .	1.0	0